These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The combined treatment with prednisolone and recombinant alpha 2-interferon of patients with chronic hepatitis B: the factors influencing the immune response].
    Author: Fedorchenko SV, Vovk AD, Rybalko SL.
    Journal: Ter Arkh; 1994; 66(2):24-9. PubMed ID: 8160138.
    Abstract:
    The study included 39 patients with chronic HBeAg and DNA HBV-positive hepatitis B. 18 patients received combined therapy with prednisolone and recombinant interferon. Pretreatment investigations involved assessment of the basic virus replication by HBeAg, IgM anti-HBc, RPSHA titers, of DNA HBV concentration, alanine aminotransferase activity. The serum was examined for antibodies to alpha 2-interferon using enzyme immunoassay. The treatment resulted in disappearance of HBeAg in 70.6% of the examinees, DNA HBV in 66.6% of them. AlAT activity returned to normal in 58.8% of the patients. HBeAg and HBsAg were not registered in 5.6% of the patients. In 2 out of 4 nonresponders antibodies to alpha 2-interferon were absent. It is shown serologically that patients with initially low HBeAg, DNA HBV, high activity of AlAT, high titers IgM anti-HBc, no antibodies to alpha 2-interferon have the most favourable prognosis of the hepatitis.
    [Abstract] [Full Text] [Related] [New Search]